Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
About this item
Full title
Author / Creator
Publisher
Alexandria, VA: American Diabetes Association
Journal title
Language
English
Formats
Publication information
Publisher
Alexandria, VA: American Diabetes Association
Subjects
More information
Scope and Contents
Contents
OBJECTIVE: Interleukin (IL)-1 impairs insulin secretion and induces β-cell apoptosis. Pancreatic β-cell IL-1 expression is increased and interleukin-1 receptor antagonist (IL-1Ra) expression reduced in patients with type 2 diabetes. Treatment with recombinant IL-1Ra improves glycemia and β-cell function and reduces inflammatory markers in patients...
Alternative Titles
Full title
Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pascalfrancis_primary_21938979
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pascalfrancis_primary_21938979
Other Identifiers
ISSN
0149-5992,1935-5548
E-ISSN
1935-5548
DOI
10.2337/dc09-0533
